Celldex (CLDX) AI Stock Analysis

• Market Cap: $1.42B
• Dividend Yield: N/A
• Average Volume (3M): 903.58K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.49
• Revenue Growth: 24.49%
• EPS Growth: 5.14%
• Country: US
• Employees: 186
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.81
• Shares Outstanding: 66,394,240
• 10 Day Avg. Volume: 1,191,475
• 30 Day Avg. Volume: 903,584
• PEG Ratio: 0.76
• Price to Book (P/B): 1.96
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.00
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 41.43
• Enterprise Value/Gross Profit: 229.06
• Enterprise Value/Ebitda: -1.85
• 1Y Price Target: $61.00
• Price Target Upside: 194.54% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 62 Neutral
• Price Target: $22.50 ▲(8.64%Upside)

Celldex's score reflects strong technical momentum and positive corporate events, but is tempered by financial challenges and a lack of profitability. The company's strategic initiatives and balance sheet strength are promising, but cash flow issues and negative earnings impact the overall score.

Positive Factors

Clinical Trial Progress

Barzolvolimab holds the most compelling clinical profile to date across two large Phase 2 urticaria studies, and is meaningfully ahead of competitors with enrollment well underway in the Phase 3 EMBARQ trials.

Dosing Advantages

Barzo's monthly dosing is appealing compared to the high and weekly dosing of dupi, especially for a chronic condition like EOE.

Market Potential

The potential of barzo in EOE is underappreciated by the market, with a sound biological rationale and de-risked profile.

Negative Factors

Market Sentiment

Short interest in Celldex stock is relatively high at 14% of the float.

Regulatory Challenges

Barzo, a mast cell depleter, will not directly reduce eosinophils, which is required for FDA approval in EOE.

Side Effect Risks

There is a risk of dose-dependent side effects like neutropenia and hair/skin color changes due to barzo's higher dose used in Ph2 EOE trials.

Celldex Business Overview & Revenue Model

Company Description

Celldex Therapeutics, Inc. (CLDX) is a biopharmaceutical company focused on the development and commercialization of targeted therapeutics to address unmet medical needs in oncology. The company's core products include a pipeline of clinical-stage drug candidates designed to modulate the immune system and target specific tumor antigens. Celldex leverages advanced technologies to create innovative treatment options aimed at improving patient outcomes in various cancer indications.

How the Company Makes Money

Celldex makes money primarily through the development and eventual commercialization of its drug candidates. The company's revenue model includes licensing agreements, collaboration partnerships, and milestone payments from larger pharmaceutical companies that it partners with during the drug development process. Revenue is also generated from government grants and research funding, which support clinical trials and research initiatives. Upon successful approval and commercialization of its drugs, Celldex anticipates revenue from product sales in the oncology market. Strategic partnerships and collaborations are integral to its financial model, as these alliances provide essential funding and shared resources for developing and marketing its therapeutic products.

Celldex Financial Statement Overview

Summary

Celldex faces financial challenges typical of biotech firms, with negative profitability and high R&D expenses. Strong balance sheet with low debt is a positive, but significant losses and cash flow issues persist.

Income Statement

Celldex shows modest revenue growth with a 7.7% increase in the most recent TTM period. However, the company is struggling with substantial losses, as evidenced by negative net income and EBIT margins. The gross profit margin remains positive at 78.6%, but the net profit margin is significantly negative at -2366.6%, indicating the company is not yet profitable. The biotechnology industry often experiences prolonged periods of negative earnings due to high R&D expenses.

Balance Sheet

The balance sheet is relatively strong with a high equity ratio of 95.1%, which denotes a solid capital structure. The debt-to-equity ratio is very low at 0.005, suggesting minimal leverage. Despite these strengths, the company is facing consistent net losses, impacting its return on equity, which stands at -25.4% in the TTM period.

Cash Flow

Celldex's cash flow is challenged, with a negative free cash flow of -$171.9 million in the TTM period. The operating cash flow to net income ratio is slightly positive at 0.96, indicating some alignment with reported losses. However, the free cash flow to net income ratio is negative, reflecting operational cash burn. Positive financing cash flow suggests reliance on external funding.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
7.56M	7.02M	6.88M	2.36M	4.65M	7.42M
	Gross Profit
5.94M	7.02M	3.88M	957.00K	1.58M	-35.12M
	EBIT
-217.21M	-195.08M	-154.54M	-115.23M	-71.24M	-63.35M
	EBITDA
-213.94M	-191.90M	-139.03M	-104.20M	-66.08M	-45.64M
	Net Income Common Stockholders
-178.85M	-157.86M	-141.43M	-122.78M	-70.51M	-59.78M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
64.38M	725.28M	423.60M	304.95M	408.25M	194.42M
	Total Assets
122.93M	792.34M	465.63M	352.74M	444.65M	235.84M
	Total Debt
3.66M	3.81M	2.54M	4.03M	3.04M	3.48M
	Net Debt
-7.58M	-24.54M	-32.27M	-25.40M	-36.10M	-40.35M
	Total Liabilities
28.91M	45.34M	36.46M	26.53M	25.18M	26.48M
	Stockholders Equity
94.03M	747.00M	429.17M	326.20M	419.48M	209.36M
Cash Flow		Free Cash Flow
-171.92M	-159.70M	-109.11M	-105.56M	-62.16M	-41.96M
	Operating Cash Flow
-171.51M	-157.78M	-107.29M	-103.73M	-60.91M	-40.40M
	Investing Cash Flow
68.03M	-290.13M	-105.78M	89.94M	-216.16M	-98.22M
	Financing Cash Flow
5.54M	441.45M	218.46M	4.08M	272.37M	171.23M

Celldex Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 20.71
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDX, the sentiment is Positive. The current price of 20.71 is above the 20-day moving average (MA) of 20.03, above the 50-day MA of 19.10, and below the 200-day MA of 25.56, indicating a neutral trend. The MACD of 0.23 indicates Negative momentum. The RSI at 55.23 is Neutral, neither overbought nor oversold. The STOCH value of 69.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLDX.

Celldex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	77 Outperform	$1.09B	17.12	21.57%	―	25.92%	―
CLDX	62 Neutral	$1.42B	―	-23.20%	―	24.49%	5.14%
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
WVE	53 Neutral	$1.11B	―	-105.50%	―	-7.06%	-57.17%
SNDX	48 Neutral	$985.24M	―	-93.70%	―	―	-25.83%
DYN	43 Neutral	$1.67B	―	-64.01%	―	―	14.93%
IOVA	41 Neutral	$684.57M	―	-51.85%	―	11070.12%	32.07%

Celldex Corporate Events

Celldex Approves Equity Plan Amendment and Elects New Director

On June 5, 2025, Celldex Therapeutics held its Annual Meeting of Stockholders, where several key decisions were made, including the approval of an amendment to the 2021 Omnibus Equity Incentive Plan, increasing the shares available for issuance by 2,000,000. Additionally, Denice M. Torres was elected to the Board of Directors, bringing extensive leadership experience from the pharmaceutical and consumer healthcare sectors. The election of new board members and the amendment to the equity plan are expected to bolster Celldex’s strategic growth and operational capabilities as it advances its clinical programs, particularly with the promising drug barzolvolimab.

The most recent analyst rating on (CLDX) stock is a Buy with a $74.00 price target. To see the full list of analyst forecasts on Celldex stock, see the CLDX Stock Forecast page.